Newsletters

Journalism of Courage

Ranbaxy Laboratories Limited: A Legacy of Pharmaceuticals Ranbaxy Laboratories Limited, an Indian multinational pharmaceutical company, operated from 1961 to 2014. Its history is marked by significant transitions and ultimately, acquisition. Going public in 1973, Ranbaxy experienced two major ownership changes. In 2008, Daiichi Sankyo, a Japanese pharmaceutical giant, secured a controlling stake. However, Ranbaxy's final chapter involved its complete acquisition by Sun Pharma in 2014, an all-stock deal that marked the end of an era. This acquisition, by the world's fifth-largest specialty generic pharmaceutical company, brought in new management to address lingering controversies that had plagued Ranbaxy. The merger effectively integrated Ranbaxy's operations and assets within Sun Pharma's global network, concluding a chapter in Indian pharmaceutical history marked by both growth and substantial challenges. The legacy of Ranbaxy continues to influence the Indian pharmaceutical landscape.

Image Source : Wikipedia

Company type Subsidiary
Industry Pharmaceuticals
Founded 1961
Founders Ranbir Singh, Gurbax Singh
Headquarters Gurgaon, Haryana, India
Number of employees 10,983 <small>(2012)</small>
Parent Sun Pharmaceuticals

Related Other Pages:

Berkshire Hathaway,

MyGate and

Motherson Sumi Systems

Ranbaxy Laboratories history

Last Updated : 25/03/25, 11:15 PM

Ranbaxy: A Pharmaceutical Pioneer Founded in 1937 by Ranbir Singh and Gurbax Singh as a Shionogi distributor, Ranbaxy's name reflects its founders. Bhai Mohan Singh acquired the company in 1952, and its expansion accelerated after Parvinder Singh joined in 1967. By 2005, Ranbaxy achieved US$1.178 billion in global sales, with 75% from overseas markets. A patent dispute with Pfizer over Lipitor temporarily impacted the company's share price in 2005, but a 2008 settlement allowed Ranbaxy to sell generic versions of Lipitor and Caduet in the US from 2011. The FDA granted Ranbaxy 180-day exclusivity for Simvastatin (Zocor) in 2006. In 2011, Ranbaxy secured FDA approval for its generic Lipitor. Daiichi Sankyo acquired a majority stake in Ranbaxy in 2008 for $4.6 billion, expanding Daiichi Sankyo's operations significantly. Malvinder Singh remained CEO. Ranbaxy received recognition, including the OTC Company of the Year award in 2011, and featured in Brand Trust Reports. Finally, in 2014, Sun Pharmaceutical Industries acquired Ranbaxy's remaining shares from Daiichi Sankyo in a $4 billion deal, marking the end of an era for the once-independent pharmaceutical giant. Daiichi Sankyo retained a 9% stake in Sun Pharmaceutical.